Type 2 diabetes- Pipeline Insight, 2026

DelveInsight’s, “Type 2 diabetes- Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Type 2 diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Type 2 diabetes: Understanding

Type 2 diabetes: Overview

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from a combination of insulin resistance and progressive β-cell dysfunction. It accounts for nearly 90% of all diabetes cases and is strongly associated with risk factors such as obesity, physical inactivity, and unhealthy dietary patterns. In the early stages, the body compensates for insulin resistance by increasing insulin secretion, but over time, pancreatic β-cells fail to maintain adequate insulin levels, leading to sustained high blood glucose. Chronic hyperglycemia can cause significant damage to multiple organ systems, resulting in serious complications such as retinopathy, nephropathy, neuropathy, and cardiovascular diseases, making T2DM a major global public health concern.

The pathophysiology of Type 2 Diabetes Mellitus (T2DM) is primarily characterized by a combination of insulin resistance and progressive pancreatic β-cell dysfunction. Initially, peripheral tissues such as muscle, liver, and adipose tissue become less responsive to insulin, leading to reduced glucose uptake and increased hepatic glucose production. To compensate, pancreatic β-cells increase insulin secretion and maintain near-normal glucose levels. However, over time, β-cell function declines, resulting in inadequate insulin secretion and persistent hyperglycemia.

The causes of Type 2 Diabetes Mellitus primarily involve a combination of insulin resistance and inadequate insulin production. The condition develops when cells in muscles, fat, and the liver do not respond properly to insulin, leading to reduced glucose uptake and accumulation of sugar in the blood. At the same time, the pancreas is unable to produce enough insulin to maintain normal blood glucose levels. Key contributing factors include being overweight or obese and physical inactivity, which significantly increase the risk of developing the disease. As a result of these combined defects, glucose regulation is impaired, leading to persistent hyperglycemia.

The treatment of Type 2 Diabetes Mellitus (T2DM) focuses on a combination of lifestyle modifications and pharmacological therapy. The cornerstone of management is maintaining a healthy diet, increasing physical activity (about 90–150 minutes per week), and achieving weight loss, especially in obese patients. Additional medications may then be added based on patient needs, including sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors. Treatment is individualized, with goals such as maintaining HbA1c below 7%, controlling blood pressure and lipid levels, and preventing complications through regular monitoring and comprehensive care.

""Type 2 diabetes- Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type 2 diabetes pipeline landscape is provided which includes the disease overview and Type 2 diabetes treatment guidelines. The assessment part of the report embraces, in depth Type 2 diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 2 diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Type 2 diabetes R&D. The therapies under development are focused on novel approaches to treat/improve Type 2 diabetes.

Type 2 diabetes Emerging Drugs Chapters

This segment of the Type 2 diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Type 2 diabetes Emerging Drugs

• CT-388 : F. Hoffmann-La Roche Ltd.

CT-388 is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity, type 2 diabetes, and other obesity-related comorbidities. It aims to reduce appetite and regulate blood sugar by selectively targeting and activating both receptors which integrate nutrient-derived signals to control energy homeostasis. CT-388 was designed to have potent activation of both GLP-1 and GIP receptors, but with minimal to no ß-arrestin recruitment on either receptor. This biased signalling significantly minimises receptor internalisation and consequent desensitisation, which is expected to lead to prolonged pharmacological activity. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Type 2 diabetes.

• BGM0504 : BrightGene Health

BGM0504 is an investigational GLP-1 and GIP dual receptor agonist being developed for the treatment of Type 2 Diabetes and obesity. It works by enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite, thereby improving glycemic control and promoting weight loss. Preclinical studies have shown strong metabolic effects, including reductions in body weight and improved glucose regulation, while early Phase 1 clinical trials in humans indicate that the drug is generally well tolerated and supports once-weekly dosing with dose-dependent weight loss. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Type 2 diabetes.

• ALN-4324: Alnylam Pharmaceuticals, Inc.

ALN-4324 contains a novel RNA interference (RNAi) therapeutic to reduce the hepatic synthesis of GRB14, a negative modulator of insulin, by specifically binding to its mRNA. By reducing GRB14, insulin receptor signaling in the liver is enhanced. This enhanced insulin sensitivity is expected to improve type 2 diabetes control without the weight gain often associated with traditional insulin sensitizers ALN-4324 contains a novel RNA interference (RNAi) therapeutic to reduce the hepatic synthesis of GRB14, a negative modulator of insulin, by specifically binding to its mRNA. By reducing GRB14, insulin receptor signaling in the liver is enhanced. This enhanced insulin sensitivity is expected to improve type 2 diabetes control without the weight gain often associated with traditional insulin sensitizers. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Type 2 diabetes.

• ASC30: Ascletis Pharma Inc.

ASC30 was discovered and developed in-house at Ascletis as a first and only investigational small molecule GLP-1R fully biased agonist that can be dosed once daily orally and once monthly to once quarterly subcutaneously for the treatment of obesity, diabetes and other metabolic diseases. The drug has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) in January 2026 to begin a 13-week Phase II study of its oral small molecule glucagon-like peptide (GLP)-1, ASC30, targeting participants with type 2 diabetes (T2D) mellitus. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Type 2 diabetes.

• PS1: Pharmasaga Co. Ltd.

PS1 is an investigational small-molecule drug being developed for Type 2 Diabetes. It functions as an inhibitor of the protein Pdia4 (protein disulfide isomerase A4), which plays a key role in β-cell dysfunction and diabetes progression through increased oxidative stress. By inhibiting Pdia4, PS1 reduces reactive oxygen species (ROS) production, thereby protecting pancreatic β-cells, improving insulin secretion, and reducing cell death. Preclinical studies in diabetic animal models showed that PS1 significantly improved blood glucose levels, HbA1c, and β-cell function, and even reversed disease progression in some cases. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Type 2 diabetes.

• CAD-1005: Cadrenal Therapeutics, Inc.

CAD-1005, an investigational therapy being evaluated for suspected HIT, is a potent, highly selective small molecule inhibitor of human 12-LOX. It is currently the only selective 12-LOX inhibitor in clinical development. CAD-1005 is designed to target 12-LOX specifically, a pathway crucial to the primary immune mechanisms that cause HIT. Unlike existing therapies for HIT, which mainly focus on preventing blood clots, this approach addresses the root cause of HIT. In preclinical models, CAD-1005 has been shown to prevent or treat HIT and stop the development of thrombocytopenia and blood clots. Currently, the drug is being evaluated in the preclinical stage of its development for the treatment of Type 2 diabetes.

Further product details are provided in the report……..

Type 2 diabetes: Therapeutic Assessment

This segment of the report provides insights about the different Type 2 diabetes drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Type 2 diabetes

There are approx. 75+ key companies which are developing the therapies Type 2 diabetes. The companies which have their Type 2 diabetes drug candidates in the most advanced stage, i.e. Phase III include, F. Hoffmann-La Roche Ltd., and others.

• Phases

DelveInsight’s report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Type 2 diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Type 2 diabetes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 2 diabetes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 2 diabetes drugs.

Type 2 diabetes Report Insights

• Type 2 diabetes Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Type 2 diabetes Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Type 2 diabetes drugs?
• How many Type 2 diabetes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type 2 diabetes?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type 2 diabetes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Type 2 diabetes and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• F. Hoffmann-La Roche Ltd.
• BrightGene Health
• Alnylam Pharmaceuticals, Inc.
• Ascletis Pharma Inc. Pharmasaga Co. Ltd.
• Pharmasaga Co. Ltd.
• Cadrenal Therapeutics, Inc.
• Eli Lilly and Company
• Novo Nordisk A/S
• Gan & Lee Pharmaceuticals
• AstraZeneca
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
• Amgen Inc.
• Beijing Zhitai Biomedical Technology Co., Ltd.
• Oramed
• Vertex Pharmaceuticals Incorporated
• Gilead Sciences
• Sun Pharmaceutical Industries Ltd.
• ProKidney Corp.
• Merck Sharp & Dohme LLC
• Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
• Adocia
• Tonghua Dongbao Pharmaceutical Co.,Ltd.
• Abarceo Pharma AB

Key Products

• CT-388
• BGM0504
• ALN-4324
• ASC30
• CAD-1005
• PS1
• Retatrutide
• CagriSema
• GZR18
• AZD5004
• Aleniglipron
• Maridebart cafraglutide
• ZT-002
• ORMD 0901
• VX-880
• GS-4571
• Utreglutide (GL0034)
• Rilparencel
• MK-2828
• HDM1002
• THDB0206
• RG-6652
• zimislecel

Please Note: It will take 3-4 business days to complete the report upon order confirmation. Show more